Industry Newsbiopharmadrug developmentpublic offering
Praxis Precision Secures $621M From Public Offering
|
4.0
Praxis Precision Medicines said its recent public offering generated about $621 million in net proceeds, and on January 12 Wedbush analyst Laura Chico raised the price target to $95 from $83 while maintaining an Underperform rating. The stock has gained over 420% in three months, and Wall Street consensus lists a Strong Buy with a one-year average target of $456.71. The company plans two FDA NDA submissions in February and multiple readouts over the next 12–24 months.
Scoring Rationale
Moderate investor relevance and confirmed offering; limited industry impact and company-specific focus reduce broader significance.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
